https://www.selleckchem.com/pr....oducts/3-methyladeni
l outcomes to RT 027. These findings can help to better understand the clinical significance of this and future emerging ribotypes.Avelumab can kill cancer cells through immune checkpoint inhibition and antibody-dependent cell-mediated cytotoxicity (ADCC). Here, we analyzed the clinical efficacy and adverse events (AEs) in 3935 cancer patients from 21 trials. Compared with conventional treatment, avelumab monotherapy was associated with more tumor responses and less AEs. The pooled objective response rate was 14.18 % (95 % CI, 1
Like
Comment
Share
